MIGALASTAT
Manner of administration:Oral
Restriction
Indication: Fabry disease
Treatment phase: Initial treatment
Restriction
Indication: Fabry disease
Treatment phase: Continuing treatment
Restriction
Indication: Fabry disease
Treatment phase: Grandfather arrangement (transition from LSDP-funded Fabry disease therapy)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 14 | # of repeats: 6 | DPMQ: $28,076.78 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Galafold | |||||